• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
High purity nutritional supplement R-lipoic acid powder
Alpha lipoic acid powder
Chromloong
Alphasil Columns
AlphaHybrid Columns
Marsil Columns

Richmond-based E. Claiborne Robins Co. Inc. lawsuit against Teva Pharmaceutical seeks $110 million

firstwordpharmaDecember 02, 2018

Tag: lawsuit , Teva Pharmaceutical , E. Claiborne Robins , lawsuit

  • Former specialty drug company E. Claiborne Robins has filed a $110-million lawsuit suit against Teva in a dispute over a 2007 asset purchasing agreement, reported Richmond.com.

  • The lawsuit accuses Teva of failing to live up to "commercially reasonable efforts" to market a patented muscle relaxer called Amrix developed by Robins and sold in 2007 to Cephalon, which Teva went on to acquire in 2011.

  • The suit alleges that under an agreement formula, Teva must pay Robins $97.5 million, and with interest added, the amount rises to at least $110 million.

Previous:Medicines for Europe Welcomes Competitiveness Council Discussion to Stop Delocalisation of Medicines Manufacturing. It is Time to Effectively Position Europe as a Global Hub for the Production of Medicines

Next:FDA Could Improve Designation Review Consistency; Rare Disease Drug Development Challenges Continue

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Richmond-based E. Claiborne Robins Co. Inc. lawsuit against Teva Pharmaceutical seeks $110 million | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides
CEFALEXINE cephalosporins

CEFALEXINE cephalosporins
CEFRADINE cephalosporins

CEFRADINE cephalosporins
CEFADROXIL cephalosporins

CEFADROXIL cephalosporins
CEFIXIME cephalosporins

CEFIXIME cephalosporins
CEFATHIAMIDINE cephalosporins

CEFATHIAMIDINE cephalosporins
CEFMINOX SODIUM cephalosporins

CEFMINOX SODIUM cephalosporins
CEFOXITIN SODIUM cephalosporins

CEFOXITIN SODIUM cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service